Information
-
Patent Grant
-
4128661
-
Patent Number
4,128,661
-
Date Filed
Tuesday, November 22, 197746 years ago
-
Date Issued
Tuesday, December 5, 197845 years ago
-
Inventors
-
Original Assignees
-
Examiners
- Meyers; Albert T.
- Robinson; D. W.
Agents
- Ladas, Parry, Von Gehr, Goldsmith & Deschamps
-
CPC
-
US Classifications
Field of Search
-
International Classifications
-
Abstract
The compound (bis-diethylamine)2,5-dihydroxybenzene-1,4-disulfonate is useful as a medicament against glaucoma. .
Description
The compound (bis-diethylamine)2,5-dihydroxybenzene-1,4-disulfonate of formula ##STR1## which has the generic international non-proprietary name bis-diethylamine salt of Persylate is known to reduce the bleeding time of the rabbit ear in the test method according to Roskam (see U.S. Pat. No. 4,038,390).
It has now surprisingly be found that this persylate has the ability to lower intra-ocular pressure (IOP).
In an animal model, this persylate was found to have a favorable influence of IOP.
In a study, intra-cameral perfusion with this persylate (400 .mu.g/ml) in 6 anaesthetized rabbits, employing a technique of constant pressure infusion has resulted in a significant increase (57%) in outflow facility.
A clinical trial demonstrated the interest of this persylate in the treatment of glaucoma.
20 PATIENTS WITH CHRONIC SIMPLE GLAUCOMA (OPEN-ANGLE GLAUCOMA) WERE TREATED DURING 6 MONTHS WITH A DAILY DOSAGE OF 750 MG OF THIS PERSYLATE IN TABLET FORM. The individual patient results for IOP before and after treatment are shown in Table I.
The annexed drawing shows the evolution of IOP (mean value of 20 patients results) after the 6 months treatment period with 750 mg of this persylate per day in tablet form.
Also show in this chart is the evolution of the mean value of 10 patients results during 4 months with 1500 mg per day incapsule form. It can be seen that the higher dose allows a faster lowering of IOP.
Useful dosage range: 100 mg - 5 g daily, a higher dose being preferred for initial treatment and a lower dosage for maintenance treatment.
The compound can be administered in any suitable galenic form, such as tablets, injectable solutions, capsules, suppositories, etc.
______________________________________ IOP (mm Hg) Before treatment After treatmentPATIENT NO. Right/left Eye Right/left Eye______________________________________1 28/29 22/212 26/27 20/203 30/35 23/264 36/32 29/255 30/30 23/236 23/23 16/167 27/28 20/228 30/31 23/239 29/31 23/2410 28/28 19/1711 31/29 23/2112 28/27 22/2313 33/28 22/2114 30/32 19/2015 28/27 22/2116 30/28 22/2317 29/32 22/2318 27/29 21/2119 32/29 23/2420 31/28 24/22______________________________________
Claims
- 1. A method of treating a human being suffering from glaucoma, comprising administering in galenic form to said human a pharmaceutically effective amount of (bis-diethylamine)2,5-dihydroxybenzene-1,4-disulfonate in a pharmaceutically acceptable carrier.
- 2. The method according to claim 1, wherein said pharmaceutically effective amount is from 100 mg to 5 g per day of said (bis-diethylamine) 2,5-dihydroxybenzene-1,4-disulfonate.
- 3. The method according to claim 2, wherein said (bis-diethylamine) 2,5-dihydroxybenzene-1,4-disulfonate in a pharmaceutically-acceptable carrier is orally administered.
US Referenced Citations (5)